| Company Name: |
SPIRO PHARMA |
| Tel: |
|
| Email: |
eric_feng1954@126.com |
- EGFR-IN-12
-
- $75.00
-
2026-07-27
- CAS:879127-07-8
- Purity: 99.76%
- Supply Ability: 10g
|
| | EGFR inhibitor Basic information |
| Product Name: | EGFR inhibitor | | Synonyms: | EGFR inhibitor;CyclopropanecarboxaMide, N-[3-[[6-[[3-(trifluoroMethyl)phenyl]aMino]-4-pyriMidinyl]aMino]phenyl]-;EGFR Inhibitor [879127-07-8];EGFR inhibitor 324674;EGFR inhibitor(YUN27078);EGFR Inhibitor [879127-07-8] - EGFR Inhibitor 324674;N-(3-((6-((3-(Trifluoromethyl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)cyclopropanecarboxamide;EGFR,EGFRIN12,autophosphorylation,anti-proliferation,4,6-disubstituted,antitumor,kinases,Epidermal growth factor receptor,inhibit,EGFR IN 12,AKT,pyrimidine,ErbB-1,Apoptosis,Inhibitor,HER1,Tyrosine | | CAS: | 879127-07-8 | | MF: | C21H18F3N5O | | MW: | 413.4 | | EINECS: | | | Product Categories: | A EGFR tyrosine kinase inhibitor. | | Mol File: | 879127-07-8.mol |  |
| | EGFR inhibitor Chemical Properties |
| Boiling point | 605.9±55.0 °C(Predicted) | | density | 1.456±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | insoluble in H2O; insoluble in EtOH; ≥60.7 mg/mL in DMSO | | form | crystalline solid | | pka | 14.50±0.70(Predicted) | | color | Off-white to light yellow | | InChI | 1S/C21H18F3N5O/c22-21(23,24)14-3-1-4-15(9-14)27-18-11-19(26-12-25-18)28-16-5-2-6-17(10-16)29-20(30)13-7-8-13/h1-6,9-13H,7-8H2,(H,29,30)(H2,25,26,27,28) | | InChIKey | YOHYSYJDKVYCJI-UHFFFAOYSA-N | | SMILES | FC(F)(F)c1cc(ccc1)Nc2ncnc(c2)Nc3cc(ccc3)NC(=O)C4CC4 |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids |
| | EGFR inhibitor Usage And Synthesis |
| Uses | EGFR Inhibitor is a highly selective, cell-permeable EGFR inhibitor. | | Biological Activity | egfr inhibitor is a cell permeable, pyrimidine compound that selectively inhibits the egfr kinase with ic50 value of 21 nm [1].egfr is a transmembrane protein, and is a receptor for members of epidermal growth factor family. the binding of egfr with its ligands induces receptor dimerization and tyrosine autophosphorylation, and leads to cell proliferation. the overactivity of egfr tyrosine kinases is associated with a number of cancers, inhibition of egfr can downregulate antiapoptotic proteins such as surviving and upregulate proapoptotic proteins such as bim. thus, egfr inhibitor can induce cell apoptosis, resulting in anti-tumor effectivity [2].egfr inhibitor inhibited egfr kinase in vitro and blocks receptor autophosphorylation in cells. egfr inhibitor also inhibited l858r and l861q egfr mutants with ic50 values of 63 and 4 nm, respectively [1]. | | IC 50 | EGFR (WT): 21 nM (IC50); EGFRL858R: 63 nM (IC50); EGFRL861Q: 4 nM (IC50); HER4: 7640 nM (IC50) | | references | 1. q. zhang, y. liu, f. gao, et al. discovery of egfr selective 4,6-disubstituted pyrimidines from a combinatorial kinase-directed heterocycle library. journal of the american chemical society 128(7), 2182-2183 (2006). 2. f. ciardiello, g. tortora. egfr antagonists in cancer treatment. new england journal of medicine 358(11), 1160-1174 (2008). |
| | EGFR inhibitor Preparation Products And Raw materials |
|